Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol
Open accessThe DOI matches its Crossref record; 51 of the 52 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Flavaglines are a family of natural products from the genus Aglaia that exhibit anti-cancer activity in vitro and in vivo and inhibit translation initiation. They have been shown to modulate the activity of eIF4A, the DEAD-box RNA helicase subunit of the eukaryotic initiation factor (eIF) 4F complex, a complex that stimulates ribosome recruitment during translation initiation. One flavagline, silvestrol, is capable of modulating chemosensitivity in a mechanism-based mouse model. METHODOLOGY/PRINCIPAL FINDINGS: Among a number of flavagline family members tested herein, we find that silvestrol is the more potent translation inhibitor among these. We find that silvestrol impairs the ribosome recruitment step of translation initiation by affecting the composition of the eukaryotic initiation factor (eIF) 4F complex. We show that silvestrol exhibits significant anticancer activity in human breast and prostate cancer xenograft models, and that this is associated with increased apoptosis, decreased proliferation, and inhibition of angiogenesis. We demonstrate that targeting translation by silvestrol results in preferential inhibition of weakly initiating mRNAs. CONCLUSIONS/SIGNIFICANCE: Our results indicate that silvestrol is a potent anti-cancer compound in vivo that exerts its activity by affecting survival pathways as well as angiogenesis. We propose that silvestrol mediates its effects by preferentially inhibiting translation of malignancy-related mRNAs. Silvestrol appears to be well tolerated in animals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Figures
![Figure 1 Structure-activity relationship analysis of cyclopenta[b]benzofurans. A. Chemical structure of cyclopenta[b]benzofurans tested in this study. B. Effect of cyclopenta[b]benzofurans on cap- and HCV-mediated translation initiation. Krebs-2 translation extracts were programmed with FF/HCV/Ren mRNA and vehicle (MeOH) or 50 µM compound. The relative activity (compared to DMSO controls) from 3 independent translation reactions is presented along with the standard error of the mean. [The partial inhibition of HCV-mediated translation has been previously documented [4].] C. Dose–dependent inhibition of translation by flavaglines in RRL extracts. Extracts were programmed with FF/HCV/Ren mRNA and firefly luciferase values determined and set relative to translations containing vehicle alone. The values obtained are the average of 2 experiments. D. Dose–dependent inhibition of translation by flavaglines in MDA-MB-231 cells. Compounds were added to cells in culture at the indicated dose for 1 h. 35S-methionine was added to cells 15 min before harvesting, after which TCA precipitable counts were determined and standardized against total protein content. Values are set relative to those obtained from vehicle-treated cells. The values obtained are the average of 2 experiments.](https://figures.cochat.ai/paper-figures/ab1d369ba4e34738851f06e9354cc768/antitumor-activity-and-mechanism-of-action-of-the-cyclopenta-b-benzofuran-figure-1.jpg)
![Figure 2 Silvestrol stimulates binding of eIF4A to mRNA. A. Silvestrol stimulates retention of eIF4AIf to mRNA. Radiolabeled CAT mRNA was incubated with eIF4AIf and ATP in the presence of vehicle (DMSO), pateamine A (PatA), hippuristanol [45], or silvestrol (Sil) for 2 min after which time the reactions were applied to nitrocellulose filters, washed and dried. The amount of radiolabeled mRNA retained on the filters was determined by scintillation counting. The results are the average of three experiments with the standard error of the mean shown. B. Silvestrol stimulates cap-dependent crosslinking of eIF4Ac. Chemical crosslinking of initiation factors to oxidized 32P-cap labeled CAT mRNA. The presence of 20 µM silvestrol is indicated above the panel. The gel was dried and exposed to X-ray film (Kodak) at −80°C with an intensifying screen. C. Left Panel: Silvestrol reduces the amount of eIF4Ac in the eIF4F complex. RSW was incubated with vehicle (0.5% DMSO) or 50 µM silvestrol for 1 h followed by m7GTP-affinity purification. Reactions were resolved on a 10% SDS-polyacrylamide gel followed by Western blot analysis. Right Panel: MDA-MB-231 cells were treated with 25 nM silvestrol for 4 h, after which time, cell extracts were prepared and m7GTP-affinity purifications performed. Reactions were resolved on a 10% SDS-polyacrylamide gel followed by Western blot analysis. D. Krebs-2 extracts were treated with 50 µM of silvestrol for 10 min at 30°C. After incubation, poly (rG)-affinity purifications were performed. Eluates were resolved on a 10% SDS polyacrylamide gel and analyzed by Western blotting.](https://figures.cochat.ai/paper-figures/79160cceef1d4967ae153d0785590ced/antitumor-activity-and-mechanism-of-action-of-the-cyclopenta-b-benzofuran-figure-2.jpg)




Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“eIF4A inhibitors, which target both isoforms, suppress translation of key oncogenes and have demonstrated antitumor activity in a variety of cancers (15, 17, 19–22).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This supports the idea that increased expression of eIF4A2 may protect cells from the effects of eIF4A1 inhibition; rocaglates such as [-]CR-1-31B inhibit both isoforms, which may contribute to their efficacy (21, 34).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“This supports the idea that increased expression of eIF4A2 may protect cells from the effects of eIF4A1 inhibition; rocaglates such as [-]CR-1-31B inhibit both isoforms, which may contribute to their efficacy (21, 34).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [21]
Experimental — accuracy not yet measuredThe cited source says what the claim attributes to it.
In the citing paper
“Our results build on studies in mouse models of other cancers, including lymphoma, leukemia, breast, prostate, and pancreatic cancer, supporting the tolerability and efficacy of eIF4A inhibitors (15, 17, 20, 21, 38).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [21]
The check wasn’t confident either way, so it gives no verdict — never disputed.
In the citing paper
“A synthetic eIF4A inhibitor, CR-1-31B, has shown potent activity against many cancer cell lines and promising efficacy in several mouse models (15, 17, 20, 21, 32, 33).”
From Targeting eIF4A-dependent translation in genetically complex sarcoma (2026) · cites this paper as [21]
Experimental — accuracy not yet measured
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
New Colorimetric Cytotoxicity Assay for Anticancer-Drug Screening
Skehan, P., Storeng, R., Scudiero, D., Monks, A., McMahon, J., Vistica, D., Warren, J. T., Bokesch, H., Kenney, S., & Boyd, M. R. (1990) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/82.13.1107 · Cited by 9,766
Chou, T.-C., & Talalay, P. (1984) · Advances in Enzyme Regulation · doi:10.1016/0065-2571(84)90007-4 · Cited by 7,178 · cited 1×
“. Drug interaction was assessed by the combination index method of Chou and Talalay using CalcuSyn software (BioSoft, Cambridge, UK)”
MethodCore Signaling Pathways in Human Pancreatic Cancers Revealed by Global Genomic Analyses
Jones, S., Zhang, X., Parsons, D. W., Lin, J. C.-H., Leary, R. J., Angenendt, P., Mankoo, P., Carter, H., Kamiyama, H., Jimeno, A., et al. (2008) · Science · doi:10.1126/science.1164368 · Cited by 3,969
Malignant transformation by a eukaryotic initiation factor subunit that binds to mRNA 5' cap
Lazaris-Karatzas, A., Montine, K. S., & Sonenberg, N. (1990) · Nature · doi:10.1038/345544a0 · Cited by 956
Survival signalling by Akt and eIF4E in oncogenesis and cancer therapy
Wendel, H.-G., Stanchina, E. D., Fridman, J. S., Malina, A., Ray, S., Kogan, S., Cordon-Cardo, C., Pelletier, J., & Lowe, S. W. (2004) · Nature · doi:10.1038/nature02369 · Cited by 951
Self-citationAn RNA G-quadruplex in the 5′ UTR of the NRAS proto-oncogene modulates translation
Kumari, S., Bugaut, A., Huppert, J. L., & Balasubramanian, S. (2007) · Nature Chemical Biology · doi:10.1038/nchembio864 · Cited by 822 · cited 1×
“, G-Q(+6)/RL). The G-quadruplex was modeled on one previously described to be present within the 5′ UTR of NRAS RNA and shown to mediate translational repression”
MethodMolecular mechanisms of translation initiation in eukaryotes
Pestova, T. V., Kolupaeva, V. G., Lomakin, I. B., Pilipenko, E. V., Shatsky, I. N., Agol, V. I., & Hellen, C. U. T. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.111145798 · Cited by 742
S6K1- and ßTRCP-Mediated Degradation of PDCD4 Promotes Protein Translation and Cell Growth
Dorrello, N. V., Peschiaroli, A., Guardavaccaro, D., Colburn, N. H., Sherman, N. E., & Pagano, M. (2006) · Science · doi:10.1126/science.1130276 · Cited by 731
Pestova, T. V., Shatsky, I. N., Fletcher, S. P., Jackson, R. J., & Hellen, C. U. T. (1998) · Genes & Development · doi:10.1101/gad.12.1.67 · Cited by 729
eIF-4E expression and its role in malignancies and metastases
De Benedetti, A., & Graff, J. R. (2004) · Oncogene · doi:10.1038/sj.onc.1207545 · Cited by 728
Cited by
Functional 5′ UTR mRNA structures in eukaryotic translation regulation and how to find them
Leppek, K., Das, R., & Barna, M. (2018) · Nature Reviews Molecular Cell Biology · doi:10.1038/nrm.2017.103 · Cited by 949
Translational control in cancer
Silvera, D., Formenti, S. C., & Schneider, R. J. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2824 · Cited by 821
Targeting the translation machinery in cancer
Bhat, M., Robichaud, N., Hulea, L., Sonenberg, N., Pelletier, J., & Topisirovic, I. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4505 · Cited by 799
Self-citationStress granules and neurodegeneration
Wolozin, B., & Ivanov, P. (2019) · Nature Reviews Neuroscience · doi:10.1038/s41583-019-0222-5 · Cited by 810
Stress Granules and Processing Bodies in Translational Control
Ivanov, P., Kedersha, N., & Anderson, P. (2019) · Cold Spring Harbor Perspectives in Biology · doi:10.1101/cshperspect.a032813 · Cited by 496
Metadata
- Authors
- Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., Porco, J. A., & Pelletier, J.
- Affiliations
- McGill University (CA)
- Sunnybrook Health Science Centre (CA)
- University of Vienna (AT)
- Boston University (US)
- Corresponding author
- Pelletier, Jerry
- ORCID
- Venue
- PLoS ONE
- Publisher
- Public Library of Science (PLoS)
- Published
- 2009-04-29
- Volume
- 4
- Issue
- 4
- Pages
- e5223
- ISSN
- 1932-6203 (ISSN-L)
- PMC
- PMC2671147
- OpenAlex
- W2031035517
- Cited by
- 302
- References
- 52
- Citations by year
- 2026: 8 · 2025: 10 · 2024: 10 · 2023: 24 · 2022: 12 · 2021: 22 · 2020: 15 · 2019: 23 · 2018: 28 · 2017: 14 · 2016: 25 · 2015: 13 · 2014: 24 · 2013: 18 · 2012: 18
- FWCI
- 7.64
- Type
- journal article
- Language
- en
- Open access
- gold
- doi.org
- Locations
- PLoS ONE (publishedVersion, cc-by)
- PubMed Central (publishedVersion, cc-by)
- PubMed (publishedVersion)
- Phaidra (Universität Wien) (submittedVersion, cc-by-nc-nd)
- DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
- eScholarship@McGill (McGill) (submittedVersion, cc-by)
- Figshare (submittedVersion, cc-by)
- OpenBU (Boston University) (submittedVersion)
- Funders
- Canadian Breast Cancer Research Alliance
- National Institutes of Health
- Canadian Institutes of Health Research
- National Institute of General Medical Sciences (R01GM073855)
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › RNA and protein synthesis mechanisms
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › PI3K/AKT/mTOR signaling in cancer
- Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
- Keywords
- silvestrol, flavaglines, anticancer activity, translation initiation inhibition, eIF4A, eIF4F, ribosome recruitment, apoptosis, angiogenesis inhibition, breast cancer, prostate cancer, xenograft models, Aglaia
- MeSH terms
- Animals, Antineoplastic Agents, Phytogenic, Base Sequence, Benzofurans, Breast Neoplasms, Cells, Cultured, Female, Humans, Male, Mice, Nude, Neoplasm Transplantation, Neovascularization, Pathologic, Prostatic Neoplasms, RNA, Messenger, RNA, Neoplasm, Protein Biosynthesis, Transplantation, Heterologous, Triterpenes, Eukaryotic Initiation Factor-4E, Cell Line, Tumor, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol. https://app.cochat.ai/papers/10.1371/journal.pone.0005223
- The paper
- Cencic, R., Carrier, M., Galicia-Vázquez, G., Bordeleau, M.-E., Sukarieh, R., Bourdeau, A., Brem, B., Teodoro, J. G., Greger, H., Tremblay, M. L., Porco, J. A., & Pelletier, J. (2009). Antitumor Activity and Mechanism of Action of the Cyclopenta[b]benzofuran, Silvestrol. PLoS ONE. https://doi.org/10.1371/journal.pone.0005223
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.